BOI Boiron SA

20.95USD19.10 EUR · EPA0.00%Mkt Cap: 363.72M USDP/E: 12.65

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers homeopathic medicines and homeopathic specialties; and other healthcare products, i…

Institutional holders10 on file

Key Statistics

Company
Market Cap363.72M USD
Enterprise Value334.26M USD
Revenue (TTM)543.77M USD
Gross Profit401.13M USD
Net Income (TTM)35.80M USD
Revenue/Share31.32 USD
Last Price20.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.6K
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINFR0000061129
Valuation
P/E (Trailing)12.65
P/E (Forward)8.97
PEG2.38
EV/EBITDA5.38
EV/Revenue0.61
P/S0.67
P/B0.88
EPS (TTM)1.66 USD
EPS (Forward)2.34 USD
52W Range
18.5414% of range35.37
52W High35.37 USD
52W Low18.54 USD
Profitability
Gross Margin72.98%
Oper. Margin7.89%
EBITDA Margin11.44%
Profit Margin6.51%
ROE8.31%
ROA5.42%
ROIC8.03%
ROCE7.73%
Growth
Revenue Growth-2.20%
Earnings Growth-56.80%
Cash Flow & Leverage
Operating CF58.39M USD
CapEx (TTM)25.80M USD
FCF Margin5.56%
FCF Yield8.31%
Net Debt-29.47M USD
Net Debt/EBITDA-0.47
Net Debt/FCF-0.98
Balance Sheet
Debt/Equity0.08
Current Ratio2.25
Quick Ratio1.29
Book Value/Sh23.72 USD
Cash/Share3.20 USD
Dividends
Fwd Div Rate1.48 USD
Trail. Div Rate1.48 USD
Div. Yield7.01%
5Y Avg Yield3.17%
Payout Ratio89.40%
Ex-Div DateJun 3, 2026
Pay Date—
Splits
Last Split4:1
Split DateJul 1, 2003
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.17.36M
Float2.25M
Insiders86.11%
Institutions4.85%
Technical
SMA 5021.66 (-3.3%)
SMA 20027.68 (-24.3%)
Beta0.22
S&P 52W Chg12.00%
Avg Vol (30d)4.34K
Avg Vol (10d)2.28K
Technical Indicators
RSI (14)48.9
MACD-0.0997
MACD Signal-0.1899
MACD Hist.+0.0902
BB Upper21.97 USD
BB Middle20.77 USD
BB Lower19.58 USD
BB Width11.47%
ATR (14)0.5879 USD
Vol Ratio (20d)0.08x

About Boiron (EPA: BOI)

›

Boiron (EPA: BOI) is listed on Euronext Paris, where its shares trade in EUR. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 2,623 employees.

The shares were at 19.10 EUR on 19 November 2026, down 28.2% over 52 weeks. Its 52-week range is 16.90 EUR to 32.25 EUR: the price is 40.8% below the high and 13.0% above the low.

At a market capitalisation of 331.62M EUR, it trades at 12.6 times trailing earnings and 9.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.7, a discount of 49% for BOI. It pays a dividend yielding 7.01% (it pays out 89% of its earnings), against a median of 1.90% among the dividend payers in that peer group.

Boiron reports return on equity of 8.3%, an operating margin of 7.9% and revenue down 2.2% year over year.

It holds more cash than debt, a net cash position of 26.87M EUR. Its Piotroski F-score is 5 out of 9, an average reading of its financial health.